Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Trial Profile

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGN CD70A (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 09 Jan 2019 Results (n=18) published in the Cancer.
    • 22 Aug 2018 Results (n=20) published in the Investigational New Drugs.
    • 22 Aug 2018 Status changed from discontinued to completed, according to results published in the Investigational New Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top